Anti-CD47 antibody: A new hope for cancer treatment

The efficiency and precision of cancer treatments, which may be surgical removal, radiotherapy, chemotherapy, or a combination of second and third depends upon the stage and type of cancer. Targeting CD47 and Signal inhibitory receptor alpha protein interactions (SIRPα) has evolved as one of several such methods of cancer therapy. Continue reading Anti-CD47 antibody: A new hope for cancer treatment

Thinking differently to drive innovation in cancer research

By Jenni Lacey, Cancer Research UK

At Cancer Research UK, we invest over £350 million each year on high-calibre cancer research which we believe has the potential to provide the greatest benefit to the public and cancer patients. We are always looking for novel ways to spark and fund creative ideas, and encourage fresh thinking. That’s why we’ve developed new ways of supporting research and stimulating innovation. We have funding schemes that are open to researchers from all backgrounds, including biochemists, and those not currently working in cancer research.

Continue reading Thinking differently to drive innovation in cancer research